Indeed, several clinical studies have evaluated the biotherapeutic efficacy of monoclonal antibodies specifically targeting IL-4, IL-5, and IL-13 signals in both children and adolescents with EoE.77, –79 Results showed that targeting these downstream cytokines of IL-33 could significantly reduce the infiltration of eosinophils in the esophageal mucosa, alter histopathologic features, and improve clinical manifestations,77, –79 suggesting that EoE patients might benefit from these targeting therapeutic strategies. The gene discussed is IL13; the disease is eosinophilic esophagitis.